Skip to main content

Table 4 Adjusted odds ratios and 95% confidence intervals for between-treatment comparisons*

From: Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

LDL-C < 100 mg/dL

5.29 (4.79, 5.84)

non-HDL-C < 130 mg/dL

5.08 (4.59, 5.61)

Apo B < 90 mg/dL

3.30 (2.98, 3.64)

hs-CRP < 2 mg/L

1.22 (1.12, 1.34)

hs-CRP < 1 mg/dL

1.26 (1.15, 1.39)

LDL-C < 100 & non-HDL-C < 130 mg/dL

5.18 (4.70, 5.70)

LDL-C < 100 & Apo B < 90 mg/dL

3.34 (3.02, 3.69)

LDL-C < 100 & hs-CRP < 2 mg/L

2.52 (2.30, 2.77)

LDL-C < 100 & hs-CRP < 1 mg/L

2.05 (1.84, 2.28)

  1. Apo = Apolipoprotein; EZ = ezetimibe; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein
  2. *Ratio of the predictive odds of attaining target on Statin+EZ versus statin based on the logistic model with terms for first/second line, treatment, and baseline value(s).
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X